Skip to content

Effect of Hyaluronic Acid on Oral Mucosal Wound Healing - Focus on Pain and Re-epithelisation

Effect of Hyaluronic Acid on Oral Mucosal Wound Healing - Focus on Pain and Re-epithelisation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05099718
Enrollment
25
Registered
2021-10-29
Start date
2022-01-10
Completion date
2023-05-31
Last updated
2023-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Soft Tissue Wound Healing

Brief summary

Establishment of a sufficiently wide and thick keratinized gingival/mucosal tissue cuff around teeth/implants is considered of importance for long-term stability. This can more readily be achieved by means of autogenous soft tissue grafts harvested from the palate than with soft tissue substitutes. However, this often implies the creation of an open palatal wound involving secondary intention healing. The aim of this randomized controlled, split-mouth, clinical trial is to assess the effect of a hyaluronic acid containing commercial product on wound healing and patient morbidity after palatal soft tissue harvesting. Altogether, 20 volunteers will be recruited. An individualized splint containing 2 symmetrically located contralateral cylindrical openings will be used for standardized soft tissue harvesting (6 mm in Ø, 2 mm in depth). Soft tissue grafts will be harvested randomly from the right or left side and patients will be monitored for 3 weeks followed by a 1-month wash-out period prior to harvesting the second soft tissue graft from the other side. Participants will randomly start treating the palatal wound either with the test product (GUM Aftaclear Gel, Sunstar Suisse SA, Etoy, Switzerland; 0.3%) or saline solution for 7 days to promote the healing process, which will be reversed for the second round. Patient-related outcomes (morbidity, discomfort, taste alteration, pain killer consumption), frequency of bleeding events, defect closure (area, volume), and microbial colonisation will be recorded and analysed for any differences between the control and test product. Further, in 6 additional volunteers, biopsies of the healing wound are collected in a similar fashion as described above, but with the use of a larger stent in order to harvest also pristine surrounding tissues for histological analysis; biopsies are collected up to 14 days of healing.

Interventions

PROCEDUREpalatal soft tissue harvesting

A 6x2mm palatal soft tissue graft will be harvested.

DEVICEHyaluronic acid

application 3-times per day for 7 days

application 3-times per day for 7 days

Sponsors

Malmö University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18-65 years, * systemically healthy, * healthy periodontal conditions at the experimental region or conditions not interfering with proper biopsy harvesting, * no known sensitivity to HY, * no uncontrolled diabetes mellitus, * no radiotherapy or chemotherapy, * no current pregnancy or breastfeeding, * no hormonal diseases, * no infectious diseases, * no autoimmune diseases or under immunotherapy, * no systemic bone disease, * no wound healing disorders or acute inflammatory/infectious processes, * no systemic diseases with implications on mucous membranes (e.g., Morbus Crohn), * no increased risk of bleeding (i.e., patient with coagulation disorders or under anticoagulant therapy, and * no heavy smokers (i.e., no regular tobacco consumption \> 10 cigarettes/day).

Exclusion criteria

* not meeting the inclusion criteria.

Design outcomes

Primary

MeasureTime frameDescription
pain / discomfort (burning) perception by means of a 100 mm VAS3 days0 indicates no pain, 100 indicates maximum pain

Secondary

MeasureTime frameDescription
disturbance while eating or drinking by means of a 100 mm VAS3 days0 indicates no disturbance, 100 indicates maximum disturbance
taste alteration experience by means of a 100 mm VAS3 days0 indicates no alteration, 100 indicates maximum alteration
frequency of re-bleeding3 daysnumber of events
re-epithelialised defect area (by means of standardized photographs)3 daysmm2
pain killer consumption3 daysamount of pills taken
changes in total and specific bacterial counts3 dayslog values
defect volume fill by overlay of the intraoral scans3 daysmm3
food restrictions (yes/no)3 days
re-epithelisation by colorimetric digital assessment of the calibrated photographs3 dayscolorimetric assessment

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026